Welcome to our dedicated page for Avenue Therapeutics SEC filings (Ticker: ATXI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avenue Therapeutics, Inc. (ATXI) SEC filings page provides access to the company’s official regulatory documents, offering a detailed view of how this specialty pharmaceutical company reports its activities around neurologic disease therapies, corporate governance, and financing. These filings are submitted to the U.S. Securities and Exchange Commission and include current reports, proxy statements, and other required disclosures.
Through Form 8-K current reports, Avenue describes material events such as stock purchase agreements, corporate transactions, and shareholder meeting outcomes. For example, an 8-K filed in connection with the sale of Avenue’s majority-owned subsidiary Baergic Bio, Inc. to Axsome Therapeutics outlines the terms under which Axsome acquired 100% of Baergic’s equity and obtained worldwide commercial, development, and manufacturing rights to BAER-101 (AXS-17), as well as Avenue’s eligibility for future milestone and royalty payments. Other 8-K filings discuss the scheduling of annual meetings, shareholder proposal deadlines, and voting results on director elections and auditor ratification.
Avenue’s definitive proxy statement on Schedule 14A (DEF 14A) provides information on matters submitted to stockholders, including the election of directors, appointment of the independent registered public accounting firm, executive compensation disclosures, and governance practices. These materials also describe how stockholders may participate in virtual annual meetings and submit proposals or director nominations under the company’s bylaws and SEC rules.
In addition to narrative disclosures, Avenue’s SEC filings incorporate financial statements and risk factor discussions that the company references in its press releases. Investors can use these documents to better understand Avenue’s capital structure, voting rights, relationship with Fortress Biotech, and the risks associated with its clinical-stage pipeline, which includes AJ201, BAER-101/AXS-17-related economics, and IV tramadol.
On Stock Titan, SEC filings for ATXI are updated as they become available from EDGAR, and AI-powered tools can help summarize lengthy documents, highlight key sections on topics such as material agreements, shareholder voting outcomes, and potential milestone or royalty streams, and make it easier to navigate complex regulatory language.
Avenue Therapeutics, Inc. has scheduled its 2025 annual meeting of stockholders for December 30, 2025. The exact time and location will be provided in the company’s definitive proxy statement on Schedule 14A to be filed with the SEC.
Stockholders who want their proposals included in the proxy statement under SEC Rule 14a-8 must ensure the company receives them by November 28, 2025 and that they meet all requirements of the Exchange Act and the company’s Second Amended and Restated Bylaws. Proposals or director nominations submitted outside Rule 14a-8, including those using universal proxy rules to solicit support for alternate director nominees, also require written notice to the Corporate Secretary by November 28, 2025 at the company’s Florida headquarters address.
Avenue Therapeutics (ATXI) reported Q3 2025 results showing a net loss of $0.7 million, narrowing from the prior year. For the nine months, net loss was $2.2 million. Operating expenses fell sharply in Q3 to $0.7 million (R&D $0.18 million; G&A $0.55 million) versus $3.2 million a year ago. The company recognized $1.4 million of other revenue year-to-date tied to the AnnJi AJ201 termination and program transfer.
Cash and cash equivalents were $3.709 million at September 30, 2025. Avenue raised $2.094 million earlier in 2025 via its ATM before losing Nasdaq eligibility; the stock now trades on the OTC market. Management disclosed substantial doubt about the ability to continue as a going concern and said additional financing is needed to support a potential Phase 3 safety study of IV tramadol.
Shares outstanding were 3,183,558 as of November 12, 2025. Subsequent to quarter-end, Avenue sold Baergic to Axsome for $0.3 million upfront plus potential milestones and royalties.
Avenue Therapeutics entered a definitive agreement to sell 100% of its majority‑owned subsidiary Baergic Bio to Axsome Therapeutics for an upfront payment of $0.3 million (less transaction fees), plus contingent consideration. Axsome also obtained worldwide commercial, development, and manufacturing rights to BAER‑101, now referred to as AXS‑17, including all available nonclinical and clinical data.
Former Baergic stockholders, including Avenue, are eligible for up to $2.5 million in development and regulatory milestones for the first indication of AXS‑17 and $1.5 million for each additional indication; up to $79 million in commercial sales milestones; and a tiered mid‑to‑high single‑digit royalty on potential global net sales. Avenue expects to receive approximately 74% of all future payments and royalties under the agreement.
In connection with the disposition, Baergic approved equity awards that vest at closing: 443,578 restricted shares to CEO Alexandra MacLean, M.D. and 266,147 restricted shares to CFO/COO David Jin, entitling them to a portion of future payments and royalties tied to the agreement.